Bioresorbable Scaffold Designed for PAD Yields Good Early Results TCTMD All patients were treated with the Esprit everolimus-eluting BVS (Abbott Vascular, Santa Clara, CA), which is designed to fully metabolize within 18 months of implantation. Acute procedural success was complete, with no indications of acute scaffold ... |
